Altimmune’s (ALT) Buy Rating Reaffirmed at B. Riley

B. Riley restated their buy rating on shares of Altimmune (NASDAQ:ALT) in a research report released on Tuesday, Benzinga reports. They currently have a $20.00 price objective on the stock.

Several other research analysts also recently issued reports on the stock. Guggenheim downgraded shares of Altimmune from a buy rating to a neutral rating in a report on Monday, April 29th. JMP Securities lowered their price target on Altimmune from $25.00 to $24.00 and set a market outperform rating on the stock in a research note on Friday, May 10th. HC Wainwright reissued a buy rating and set a $12.00 price objective on shares of Altimmune in a report on Tuesday, May 14th. Finally, Piper Sandler restated an overweight rating and set a $25.00 price objective on shares of Altimmune in a research report on Friday, June 21st. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and an average price target of $18.80.

Altimmune Stock Up 3.8 %

Shares of NASDAQ ALT opened at $7.41 on Tuesday. Altimmune has a 12 month low of $2.09 and a 12 month high of $14.84. The company has a market cap of $525.37 million, a P/E ratio of -4.66 and a beta of 0.11. The business’s 50 day moving average is $7.11 and its two-hundred day moving average is $8.80.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.02. The business had revenue of $0.01 million for the quarter. Altimmune had a negative net margin of 22,645.37% and a negative return on equity of 46.96%. During the same quarter in the previous year, the business posted ($0.40) EPS. Sell-side analysts expect that Altimmune will post -1.34 earnings per share for the current fiscal year.

Institutional Trading of Altimmune

Several institutional investors have recently bought and sold shares of the stock. WealthPlan Investment Management LLC bought a new position in Altimmune during the 3rd quarter valued at about $31,000. North Star Investment Management Corp. bought a new position in shares of Altimmune in the first quarter valued at approximately $31,000. FNY Investment Advisers LLC acquired a new position in shares of Altimmune in the 4th quarter worth approximately $35,000. CANADA LIFE ASSURANCE Co bought a new stake in Altimmune during the 1st quarter worth approximately $44,000. Finally, Russell Investments Group Ltd. increased its holdings in Altimmune by 1,150.9% during the 4th quarter. Russell Investments Group Ltd. now owns 4,303 shares of the company’s stock valued at $48,000 after purchasing an additional 3,959 shares in the last quarter. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.